Exploiting novel molecular targets in gastrointestinal cancers

doi:10.3748/wjg.v13.i44.5845

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2882)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

304

HTML

2383

Tables (1-2)

195

Sum=2882

Nov 28, 2007 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 28, 2007; 13(44): 5845-5856
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5845

Table 2 Agents targeting angiogenesis in GI cancers

Agents	Tumor types	Regimen	Study Design	References
Monoclonal antibodies
Bevacizumab	Colorectal cancer	Bevacizumab/IFL	Phase III	[10]
		Bevacizumab/FOLFOX (E3200)	Phase III	[99]
		Bevacizumab/FOLFIRI	Phase II	[102]
	Pancreatic cancer	Bevacizumab/gemcitabine	Phase II/III	[103]
		Bevacizumab/gemcitabine/oxaliplatin	Phase II	[105]
		Bevacizumab/capecitabine/RT	PhaseI	[124]
VEGF decoy
VEGF-Trap	Solid tumors	I-LV5FU2/ VEGF-Trap	PhaseI	[111]
	Solid tumors	FOLFOX4/ VEGF-Trap	PhaseI	[112]
Tyrosine kinase inhibitors
Sorafenib	Hepatocellular carcinoma	Sorafenib	Phase III	[8]
	Pancreatic cancer	Gencitabine/sorafenib	PhaseI	[116]
	Colorectal cancer	Oxaliplatin/sorafenib	PhaseI	[115]
Sunitinib	Colorectal cancer	Irinotecan/cetuximab/sunitinib	PhaseI/II	[122]
	Hepatocellular carcinoma	Sunitinib	PhaseI/II	[121,123]

IFL: Irinotecan/leucovorin/bolus fluorouracil; FOLFOX: Oxaliplatin/leucovorin/infusional fluorouracil; FOLFIRI: Irinotecan/leucovorin/infusional fluorouracil; RT: Radiation therapy.

Citation: Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007; 13(44): 5845-5856
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5845.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5845